- Home
- PSA vs ALNY Comparison
PSA vs ALNY Comparison
Compare PSA & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSA
- ALNY
- Stock Information
- Founded
- PSA 1972
- ALNY 2002
- Country
- PSA United States
- ALNY United States
- Employees
- PSA N/A
- ALNY N/A
- Industry
- PSA Real Estate Investment Trusts
- ALNY Biotechnology: Pharmaceutical Preparations
- Sector
- PSA Real Estate
- ALNY Health Care
- Exchange
- PSA Nasdaq
- ALNY Nasdaq
- Market Cap
- PSA 51.9B
- ALNY 60.7B
- IPO Year
- PSA N/A
- ALNY 2004
- Fundamental
- Price
- PSA $277.96
- ALNY $446.54
- Analyst Decision
- PSA Buy
- ALNY Strong Buy
- Analyst Count
- PSA 11
- ALNY 27
- Target Price
- PSA $321.82
- ALNY $472.81
- AVG Volume (30 Days)
- PSA 988.9K
- ALNY 1.1M
- Earning Date
- PSA 10-29-2025
- ALNY 10-30-2025
- Dividend Yield
- PSA 4.15%
- ALNY N/A
- EPS Growth
- PSA N/A
- ALNY N/A
- EPS
- PSA 9.63
- ALNY 0.33
- Revenue
- PSA $4,795,182,000.00
- ALNY $3,210,070,000.00
- Revenue This Year
- PSA $1.64
- ALNY $60.04
- Revenue Next Year
- PSA $3.53
- ALNY $40.69
- P/E Ratio
- PSA $29.16
- ALNY $1,362.90
- Revenue Growth
- PSA 2.06
- ALNY 53.24
- 52 Week Low
- PSA $256.60
- ALNY $205.87
- 52 Week High
- PSA $355.87
- ALNY $495.55
- Technical
- Relative Strength Index (RSI)
- PSA 31.06
- ALNY 40.96
- Support Level
- PSA $289.52
- ALNY $436.51
- Resistance Level
- PSA $311.74
- ALNY $485.36
- Average True Range (ATR)
- PSA 6.19
- ALNY 17.28
- MACD
- PSA -3.39
- ALNY -3.49
- Stochastic Oscillator
- PSA 1.78
- ALNY 13.84
About PSA Public Storage
Public Storage is the largest owner of self-storage facilities in the US, with more than 3,300 self-storage facilities in 40 states and approximately 245 million square feet of rentable space. Through equity interests, it also has exposure to the European self-storage market through Shurgard Self Storage. The company also has a merchandise business, a third-party property management business, and an insurance business that offers products to cover losses for the goods in self-storage facilities.
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.